{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T02:07:08Z","timestamp":1788746828621,"version":"build-2803163510"},"reference-count":71,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Gates Foundation","doi-asserted-by":"publisher","award":["INV-050487"],"award-info":[{"award-number":["INV-050487"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.actbio.2025.02.035","type":"journal-article","created":{"date-parts":[[2025,2,16]],"date-time":"2025-02-16T23:19:52Z","timestamp":1739747992000},"page":"522-535","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Subcutaneous liposomal delivery improves monoclonal antibody pharmacokinetics in vivo"],"prefix":"10.1016","volume":"195","author":[{"given":"Maryam","family":"Karimi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4229-5153","authenticated-orcid":false,"given":"Arash","family":"Aslanabadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Atkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5381-9261","authenticated-orcid":false,"given":"Mahsa","family":"Hojabri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arshi","family":"Munawwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roza","family":"Zareidoodeji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4923-7661","authenticated-orcid":false,"given":"Krishanu","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parham","family":"Habibzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4620-6755","authenticated-orcid":false,"given":"Hanife Nur Karakoc","family":"Parlayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"DeVico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alonso","family":"Heredia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdolrahim","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7798-3605","authenticated-orcid":false,"given":"Mohammad M.","family":"Sajadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.actbio.2025.02.035_bib0001","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/0167-5699(92)90125-Q","article-title":"Behring's discovery of diphtheria and tetanus antitoxins","volume":"13","author":"Grundbacher","year":"1992","journal-title":"Immunol. Today"},{"issue":"2","key":"10.1016\/j.actbio.2025.02.035_bib0002","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.imlet.2015.02.005","article-title":"Edelman's view on the discovery of antibodies","volume":"164","author":"Ribatti","year":"2015","journal-title":"Immunol. Lett."},{"issue":"1","key":"10.1016\/j.actbio.2025.02.035_bib0003","article-title":"The birth of monoclonal antibodies","volume":"17","author":"Leavy","year":"2016","journal-title":"Nat. Immunol."},{"issue":"1","key":"10.1016\/j.actbio.2025.02.035_bib0004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4161\/19420862.2015.989042","article-title":"The therapeutic monoclonal antibody market","volume":"7","author":"Ecker","year":"2015","journal-title":"MAbs."},{"key":"10.1016\/j.actbio.2025.02.035_bib0005","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/B978-0-323-46143-6.00025-7","article-title":"Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery","author":"Quinteros","year":"2017","journal-title":"Nanostruct. Drug Deliv."},{"issue":"3","key":"10.1016\/j.actbio.2025.02.035_bib0006","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3390\/pharmaceutics10030083","article-title":"Overview of antibody drug delivery","volume":"10","author":"Awwad","year":"2018","journal-title":"Pharmaceutics."},{"issue":"3","key":"10.1016\/j.actbio.2025.02.035_bib0007","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/cpt.3150","article-title":"Subcutaneous administration of monoclonal antibodies: pharmacology, delivery, immunogenicity, and learnings from applications to clinical development","volume":"115","author":"Davis","year":"2024","journal-title":"Clin. Pharmacol. Therapeutic."},{"issue":"1","key":"10.1016\/j.actbio.2025.02.035_bib0008","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1186\/s12931-018-0859-z","article-title":"The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review","volume":"19","author":"Matucci","year":"2018","journal-title":"Respir. Res."},{"key":"10.1016\/j.actbio.2025.02.035_bib0009","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.addr.2020.05.009","article-title":"Predicting bioavailability of monoclonal antibodies after subcutaneous administration: open innovation challenge","volume":"167","author":"S\u00e1nchez-F\u00e9lix","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"3","key":"10.1016\/j.actbio.2025.02.035_bib0010","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/cpt.3150","article-title":"Subcutaneous administration of monoclonal antibodies: pharmacology, delivery, immunogenicity, and learnings from applications to clinical development","volume":"115","author":"Davis","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.actbio.2025.02.035_bib0011","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.3324\/haematol.2021.279459","article-title":"Final analysis of the phase III non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma","volume":"107","author":"Usmani","year":"2022","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.actbio.2025.02.035_bib0012","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.annonc.2023.05.009","volume":"34","author":"Burotto","year":"2023","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.actbio.2025.02.035_bib0013","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2217\/imt-2020-0256","article-title":"Pasotuxizumab, a BiTE((R)) immune therapy for castration-resistant prostate cancer: phase I, dose-escalation study findings","volume":"13","author":"Hummel","year":"2021","journal-title":"Immunotherapy."},{"issue":"3","key":"10.1016\/j.actbio.2025.02.035_bib0014","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.clgc.2023.02.010","article-title":"Phase 1 study of safety and preliminary clinical activity of JNJ-63898081, a PSMA and CD3 bispecific antibody, for metastatic castration-resistant prostate cancer","volume":"21","author":"Lim","year":"2023","journal-title":"Clin. Genitourin. Cancer"},{"issue":"2","key":"10.1016\/j.actbio.2025.02.035_bib0015","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2217\/imt-2020-0256","article-title":"Pasotuxizumab, a BiTE(\u00ae) immune therapy for castration-resistant prostate cancer: phase I, dose-escalation study findings","volume":"13","author":"Hummel","year":"2021","journal-title":"Immunotherapy."},{"key":"10.1016\/j.actbio.2025.02.035_bib0016","unstructured":"FDA, Liposome drug products: chemistry, manufacturing, and controls; human pharmacokinetics and bioavailability; and labeling documentation, 2018."},{"issue":"2","key":"10.1016\/j.actbio.2025.02.035_bib0017","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.ejpb.2012.02.009","article-title":"Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose","volume":"81","author":"Niu","year":"2012","journal-title":"Eur. J. Pharmaceutic. Biopharmaceutic."},{"issue":"2","key":"10.1016\/j.actbio.2025.02.035_bib0018","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.colsurfb.2008.11.033","article-title":"Modulation of the physicochemical state of interior agents to prepare controlled release liposomes","volume":"69","author":"Wang","year":"2009","journal-title":"Colloid. Surf. B: Biointerface."},{"key":"10.1016\/j.actbio.2025.02.035_bib0019","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jare.2022.05.006","article-title":"STING as an emerging therapeutic target for drug discovery: perspectives from the global patent landscape","volume":"44","author":"Kong","year":"2023","journal-title":"J. Adv. Res."},{"issue":"4","key":"10.1016\/j.actbio.2025.02.035_bib0020","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.3390\/molecules27041372","article-title":"A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives","volume":"27","author":"Liu","year":"2022","journal-title":"Molecules."},{"key":"10.1016\/j.actbio.2025.02.035_bib0021","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.colsurfb.2017.07.085","article-title":"Immunoliposomes: a review on functionalization strategies and targets for drug delivery","volume":"159","author":"Eloy","year":"2017","journal-title":"Colloids. Surf. B Biointerfaces."},{"issue":"3","key":"10.1016\/j.actbio.2025.02.035_bib0022","doi-asserted-by":"crossref","first-page":"775","DOI":"10.7150\/thno.17237","article-title":"Liposomal nanoparticles carrying anti-IL6R antibody to the tumour microenvironment inhibit metastasis in two molecular subtypes of breast cancer mouse models","volume":"7","author":"Guo","year":"2017","journal-title":"Theranostics."},{"issue":"1","key":"10.1016\/j.actbio.2025.02.035_bib0023","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ijpharm.2015.08.048","article-title":"Nanoliposome-mediated targeting of antibodies to tumors: IVIG antibodies as a model","volume":"495","author":"Nikpoor","year":"2015","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.actbio.2025.02.035_bib0024","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1016\/j.nano.2017.08.010","article-title":"Improved tumor accumulation and therapeutic efficacy of CTLA-4-blocking antibody using liposome-encapsulated antibody: in vitro and in vivo studies","volume":"13","author":"Nikpoor","year":"2017","journal-title":"Nanomedicine"},{"issue":"51","key":"10.1016\/j.actbio.2025.02.035_bib0025","article-title":"Brain-targeted liposomes loaded with monoclonal antibodies reduce alpha-synuclein aggregation and improve behavioral symptoms in Parkinson's disease","volume":"35","author":"Sela","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2025.02.035_bib0026","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jconrel.2015.02.012","article-title":"Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer's disease","volume":"203","author":"Rotman","year":"2015","journal-title":"J. Control Rel."},{"issue":"2","key":"10.1016\/j.actbio.2025.02.035_bib0027","first-page":"280","article-title":"Enhanced protection against respiratory influenza A infection in mice by liposome-encapsulated antibody","volume":"81","author":"Wong","year":"1994","journal-title":"Immunology"},{"key":"10.1016\/j.actbio.2025.02.035_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105788","article-title":"Next-generation bNAbs for HIV-1 cure strategies","volume":"222","author":"Schriek","year":"2024","journal-title":"Antiviral Res."},{"key":"10.1016\/j.actbio.2025.02.035_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2023.109809","article-title":"Broadly neutralizing antibodies targeting HIV: progress and challenges","volume":"257","author":"Paneerselvam","year":"2023","journal-title":"Clin. Immunol."},{"issue":"4","key":"10.1016\/j.actbio.2025.02.035_bib0030","first-page":"191","article-title":"Delivery platforms for broadly neutralizing antibodies","volume":"18","author":"Joshi","year":"2023","journal-title":"Curr. Opin. HIV. AIDS"},{"issue":"4","key":"10.1016\/j.actbio.2025.02.035_bib0031","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/COH.0000000000000801","article-title":"Broadly neutralizing antibodies and long-acting antiretroviral drugs as treatments for HIV","volume":"18","author":"Kuritzkes","year":"2023","journal-title":"Curr. Opin. HIV. AIDS"},{"issue":"4","key":"10.1016\/j.actbio.2025.02.035_bib0032","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/COH.0000000000000800","article-title":"Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage","volume":"18","author":"Wagh","year":"2023","journal-title":"Curr. Opin. HIV. AIDS"},{"issue":"4","key":"10.1016\/j.actbio.2025.02.035_bib0033","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1097\/COH.0000000000000802","article-title":"Broadly neutralizing antibodies for HIV treatment and cure approaches","volume":"18","author":"Frattari","year":"2023","journal-title":"Curr. Opin. HIV. AIDS"},{"issue":"2","key":"10.1016\/j.actbio.2025.02.035_bib0034","first-page":"79","article-title":"Age at ART initiation and proviral reservoir size in perinatal HIV-1 infection: considerations for ART-free remission","volume":"19","author":"Bekka","year":"2024","journal-title":"Curr. Opin. HIV. AIDS"},{"issue":"15","key":"10.1016\/j.actbio.2025.02.035_bib0035","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1091\/mbc.e13-04-0174","article-title":"Multivalent immune complexes divert FcRn to lysosomes by exclusion from recycling sorting tubules","volume":"24","author":"Weflen","year":"2013","journal-title":"Mol. Biol. Cell"},{"issue":"2","key":"10.1016\/j.actbio.2025.02.035_bib0036","doi-asserted-by":"crossref","first-page":"e49351","DOI":"10.15252\/embr.201949351","article-title":"Anti-HIV-1 antibodies trigger non-lytic complement deposition on infected cells","volume":"21","author":"Dufloo","year":"2020","journal-title":"EMBo Rep."},{"issue":"10","key":"10.1016\/j.actbio.2025.02.035_bib0037","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/s41591-021-01509-0","article-title":"Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial","volume":"27","author":"Stephenson","year":"2021","journal-title":"Nat. Med."},{"issue":"10","key":"10.1016\/j.actbio.2025.02.035_bib0038","doi-asserted-by":"crossref","first-page":"e653","DOI":"10.1016\/S2352-3018(23)00140-6","volume":"10","author":"Sobieszczyk","year":"2023","journal-title":"Lancet HIV."},{"key":"10.1016\/j.actbio.2025.02.035_bib0039","article-title":"A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV","author":"Sajadi","year":"2024","journal-title":"bioRxiv"},{"issue":"1","key":"10.1016\/j.actbio.2025.02.035_bib0040","doi-asserted-by":"crossref","first-page":"18012","DOI":"10.1038\/s41598-023-43689-4","article-title":"Application of ensemble machine learning approach to assess the factors affecting size and polydispersity index of liposomal nanoparticles","volume":"13","author":"Hoseini","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.actbio.2025.02.035_bib0041","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s12551-016-0218-6","article-title":"Dynamic light scattering: a practical guide and applications in biomedical sciences","volume":"8","author":"Stetefeld","year":"2016","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.actbio.2025.02.035_bib0042","first-page":"e57199","article-title":"Variations on negative stain electron microscopy methods: tools for tackling challenging systems","volume":"132","author":"Scarff","year":"2018","journal-title":"JoVE (J. Visual. Exp.)"},{"key":"10.1016\/j.actbio.2025.02.035_bib0043","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jconrel.2023.03.006","article-title":"A liposomal vaccine promotes strong adaptive immune responses via dendritic cell activation in draining lymph nodes","volume":"356","author":"Agallou","year":"2023","journal-title":"J. Controll. Rel."},{"issue":"4","key":"10.1016\/j.actbio.2025.02.035_bib0044","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3390\/molecules23040739","article-title":"Encapsulation of curcumin-loaded liposomes for colonic drug delivery in a pH-responsive polymer cluster using a pH-driven and organic solvent-free process","volume":"23","author":"De Leo","year":"2018","journal-title":"Molecules."},{"issue":"1","key":"10.1016\/j.actbio.2025.02.035_bib0045","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41392-023-01536-y","article-title":"Nanomedicine in cancer therapy","volume":"8","author":"Fan","year":"2023","journal-title":"Signal. Transduct. Target. Ther."},{"issue":"15","key":"10.1016\/j.actbio.2025.02.035_bib0046","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1091\/mbc.e13-04-0174","article-title":"Multivalent immune complexes divert FcRn to lysosomes by exclusion from recycling sorting tubules","volume":"24","author":"Weflen","year":"2013","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.actbio.2025.02.035_bib0047","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119211","article-title":"Preparation and characterization of stable nanoliposomal formulations of curcumin with high loading efficacy: in vitro and in vivo anti-tumor study","volume":"580","author":"Karimi","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.actbio.2025.02.035_bib0048","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12967-022-03243-8","article-title":"Identifying CCR5 coreceptor populations permissive for HIV-1 entry and productive infection: implications for in vivo studies","volume":"20","author":"Weichseldorfer","year":"2022","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.actbio.2025.02.035_bib0049","doi-asserted-by":"crossref","DOI":"10.3390\/v16030407","article-title":"Discordant antigenic properties of soluble and virion SARS-CoV-2 spike proteins","volume":"16","author":"Kumar","year":"2024","journal-title":"Viruses."},{"key":"10.1016\/j.actbio.2025.02.035_bib0050","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.3389\/fimmu.2019.01512","article-title":"Concurrent exposure of neutralizing and non-neutralizing epitopes on a single HIV-1 envelope structure","volume":"10","author":"Ray","year":"2019","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.actbio.2025.02.035_bib0051","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/intimm\/dxl110","article-title":"Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease","volume":"18","author":"Petkova","year":"2006","journal-title":"Int. Immunol."},{"issue":"3","key":"10.1016\/j.actbio.2025.02.035_bib0052","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Programs Biomed."},{"issue":"7","key":"10.1016\/j.actbio.2025.02.035_bib0053","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.cell.2018.03.061","article-title":"Identification of near-pan-neutralizing antibodies against HIV-1 by deconvolution of plasma humoral responses","volume":"173","author":"Sajadi","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.actbio.2025.02.035_bib0054","series-title":"Pharmacokinetics and Pharmacodynamics of the Advanced Drug Delivery systems, Targeting Chronic Inflammatory Lung Diseases Using Advanced Drug Delivery Systems","first-page":"551","author":"Zeeshan","year":"2020"},{"key":"10.1016\/j.actbio.2025.02.035_bib0055","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.jconrel.2018.08.001","article-title":"Subcutaneous delivery of monoclonal antibodies: how do we get there?","volume":"286","author":"Viola","year":"2018","journal-title":"J. Control Release"},{"issue":"5","key":"10.1016\/j.actbio.2025.02.035_bib0056","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s40259-018-0295-0","article-title":"Subcutaneous Administration of biotherapeutics: an overview of current challenges and opportunities","volume":"32","author":"Bittner","year":"2018","journal-title":"BioDrugs"},{"issue":"8","key":"10.1016\/j.actbio.2025.02.035_bib0057","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","article-title":"Clinical pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Keizer","year":"2010","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.actbio.2025.02.035_bib0058","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2125.2010.03647.x","article-title":"An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males","volume":"69","author":"Oh","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"11","key":"10.1016\/j.actbio.2025.02.035_bib0059","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nrclinonc.2010.139","article-title":"Delivering nanomedicine to solid tumors","volume":"7","author":"Jain","year":"2010","journal-title":"Nature Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.actbio.2025.02.035_bib0060","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0378-5173(02)00680-4","article-title":"Pulmonary administration of IgG loaded liposomes for passive immunoprophylaxy","volume":"254","author":"Dreffier","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.actbio.2025.02.035_bib0061","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2021.101534","article-title":"Innovations in lymph node targeting nanocarriers","volume":"56","author":"Kim","year":"2021","journal-title":"Semin. Immunol."},{"issue":"9","key":"10.1016\/j.actbio.2025.02.035_bib0062","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.3390\/biomedicines10092137","article-title":"Lipid-based drug delivery systems for diseases managements","volume":"10","author":"Gbian","year":"2022","journal-title":"Biomedicines."},{"key":"10.1016\/j.actbio.2025.02.035_bib0063","article-title":"Synthesis and characterization of celecoxib loaded PEGylated liposome nanoparticles for biomedical applications","volume":"18","author":"Dave","year":"2019","journal-title":"Nano-Struct. Nano-Obj."},{"issue":"2","key":"10.1016\/j.actbio.2025.02.035_bib0064","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/fluids3020036","article-title":"Comparative study of PEGylated and conventional liposomes as carriers for shikonin","volume":"3","author":"Tsermentseli","year":"2018","journal-title":"Fluids"},{"issue":"2","key":"10.1016\/j.actbio.2025.02.035_bib0065","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/pharmaceutics9020012","article-title":"Liposomal formulations in clinical use: an updated review","volume":"9","author":"Bulbake","year":"2017","journal-title":"Pharmaceutics."},{"issue":"6","key":"10.1016\/j.actbio.2025.02.035_bib0066","first-page":"2528","article-title":"Pegylated liposomes have potential as vehicles for intratumoral and subcutaneous drug delivery","volume":"6","author":"Harrington","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.actbio.2025.02.035_bib0067","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0005-2736(93)90115-G","article-title":"Subcutaneous administration of liposomes: a comparison with the intravenous and intraperitoneal routes of injection","volume":"1150","author":"Allen","year":"1993","journal-title":"Biochimica et Biophysica Acta (BBA)-Biomembranes"},{"key":"10.1016\/j.actbio.2025.02.035_bib0068","series-title":"Methods for the Preparation of Liposomes Comprising Drugs","author":"Javeri","year":"2018"},{"issue":"9","key":"10.1016\/j.actbio.2025.02.035_bib0069","doi-asserted-by":"crossref","first-page":"14022","DOI":"10.1021\/acsnano.1c05922","article-title":"Polyethylene glycol immunogenicity: theoretical, clinical, and practical aspects of anti-Polyethylene glycol antibodies","volume":"15","author":"Chen","year":"2021","journal-title":"ACS. Nano"},{"issue":"1","key":"10.1016\/j.actbio.2025.02.035_bib0070","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0005-2736(84)90521-2","article-title":"The effects of charge and size on the interaction of unilamellar liposomes with macrophages","volume":"772","author":"Schwendener","year":"1984","journal-title":"Biochimica et Biophysica Acta (BBA) - Biomembranes"},{"issue":"1","key":"10.1016\/j.actbio.2025.02.035_bib0071","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1211\/jpp.59.1.0010","article-title":"Uptake characteristics of liposomes by rat alveolar macrophages: influence of particle size and surface mannose modification","volume":"59","author":"Chono","year":"2007","journal-title":"J. Pharm. Pharmacol."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706125001291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706125001291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T03:19:14Z","timestamp":1741922354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706125001291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":71,"alternative-id":["S1742706125001291"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2025.02.035","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Subcutaneous liposomal delivery improves monoclonal antibody pharmacokinetics in vivo","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2025.02.035","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of Acta Materialia Inc.","name":"copyright","label":"Copyright"}]}}